Targeting IL-33 in patients with cancer under immune checkpoint inhibitors for a better antitumor response and prevent thromboembolism?
作者信息
Azzellino Gianluca, Ginaldi Lia, De Martinis Massimo
机构信息
University of L'Aquila Department of Clinical Medicine Public Health Life Sciences and Environment, L'Aquila, Abruzzo, Italy.
U.O.C. Area Distrettuale Adriatica, ASL 04 Teramo, Teramo, Italy.
出版信息
J Immunother Cancer. 2025 Feb 6;13(2):e010806. doi: 10.1136/jitc-2024-010806.
Abstract
摘要
相似文献
1
Targeting IL-33 in patients with cancer under immune checkpoint inhibitors for a better antitumor response and prevent thromboembolism?
J Immunother Cancer. 2025 Feb 6;13(2):e010806. doi: 10.1136/jitc-2024-010806.
2
The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.
J Thromb Haemost. 2022 Dec;20(12):2921-2929. doi: 10.1111/jth.15883. Epub 2022 Oct 7.
3
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.
Target Oncol. 2022 Sep;17(5):563-569. doi: 10.1007/s11523-022-00905-x. Epub 2022 Aug 20.
4
Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.
Invest New Drugs. 2020 Aug;38(4):1200-1206. doi: 10.1007/s10637-019-00881-6. Epub 2019 Dec 10.
5
Thrombotic Complications Associated with Immune Checkpoint Inhibitors.
Cancers (Basel). 2021 Sep 14;13(18):4606. doi: 10.3390/cancers13184606.
6
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Blood. 2021 Mar 25;137(12):1669-1678. doi: 10.1182/blood.2020007878.
7
Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management.
Curr Oncol. 2023 Mar 4;30(3):3032-3046. doi: 10.3390/curroncol30030230.
8
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.
J Immunother Cancer. 2024 Sep 3;12(9):e009236. doi: 10.1136/jitc-2024-009236.
9
Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.
Tumori. 2024 Apr;110(2):146-152. doi: 10.1177/03008916231204441. Epub 2023 Oct 11.
10
The value of performance status in predicting venous thromboembolism in lung cancer patients treated with immune checkpoint inhibitors.
Eur J Oncol Nurs. 2024 Apr;69:102527. doi: 10.1016/j.ejon.2024.102527. Epub 2024 Feb 5.
本文引用的文献
1
Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors.
Discov Oncol. 2024 Oct 5;15(1):527. doi: 10.1007/s12672-024-01416-z.
2
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.
J Immunother Cancer. 2024 Sep 3;12(9):e009236. doi: 10.1136/jitc-2024-009236.
3
Soluble ST2: A Novel Biomarker for Diagnosis and Prognosis of Cardiovascular Disease.
Curr Med Sci. 2024 Aug;44(4):669-679. doi: 10.1007/s11596-024-2907-x. Epub 2024 Aug 3.
4
IL-33/sST2 signaling pathway in pulmonary thromboembolism: A clinical observational study.
Cytokine. 2024 Oct;182:156707. doi: 10.1016/j.cyto.2024.156707. Epub 2024 Jul 30.
5
Precision medicine in COPD: A possible contribution of vitamin D?
Eur J Intern Med. 2025 Jan;131:143-144. doi: 10.1016/j.ejim.2024.07.020. Epub 2024 Jul 22.
6
COPD and the IL-33/ST2 axis targeted therapy: A role for vitamin D?
Cytokine. 2022 Oct;158:155995. doi: 10.1016/j.cyto.2022.155995. Epub 2022 Aug 8.
7
The Paradigm Change of IL-33 in Vascular Biology.
Int J Mol Sci. 2021 Dec 10;22(24):13288. doi: 10.3390/ijms222413288.
8
Conflicting vascular and metabolic impact of the IL-33/sST2 axis.
Cardiovasc Res. 2018 Oct 1;114(12):1578-1594. doi: 10.1093/cvr/cvy166.
Zotero 插件